BCN-CP01

DRUG2 trials

Sponsors

Galapagos, Galapagos Cell Therapeutics

Conditions

Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Relapsed/refractory B-Cell non-Hodgkin lymphomaRelapsed/refractory multiple myelomarelapsed/refractory chronic lymphocytic leukemia relapsed/refractory small lymphocytic leukemia

Phase 1

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

CompletedCTIS2022-501686-47-00

Galapagosrelapsed/refractory chronic lymphocytic leukemia relapsed/refractory small lymphocytic leukemia

Start: 2022-02-28End: 2025-08-25Target: 25Updated: 2025-03-21

Phase 3

A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies

RecruitingCTIS2023-510173-34-00

Galapagos Cell TherapeuticsRelapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed/refractory multiple myeloma

Start: 2024-07-26Target: 177Updated: 2025-11-28

Related Papers

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Blood2024-11-053 citations

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Blood2023-11-023 citations